Abstract: Methods of treating malignant lymphoproliferative disorders in a patient, comprising administering an effective amount of a GSK-3? inhibitor, for example 9-ING-41, are provided. Also provided are methods for treating malignant lymphoproliferative disorders comprising administering a GSK-3? inhibitor, for example 9-ING-41, in combination with a second or multiple therapeutic agents.

Abstract: Methods of treating malignant lymphoproliferative disorders in a patient, comprising administering an effective amount of a GSK-3? inhibitor, for example 9-ING-41, are provided. Also provided are methods for treating malignant lymphoproliferative disorders comprising administering a ({umlaut over (?)}8K-3? inhibitor, for example 9-ING-41, in combination with a second or multiple therapeutic agents.

Abstract: Methods of treating malignant lymphoproliferative disorders in a patient, comprising administering an effective amount of a GSK-3? inhibitor, for example 9-ING41, are provided. Also provided are r s for treating malignant lymphoproliferative disorders comprising administering a ({umlaut over (?)}8K-3? inhibitor, for example 9-ING-41, in combination with a second or multiple therapeutic agents.

Abstract: The present invention concerns the detection of gene products resulting from chromosomal translocations, including fusion proteins comprising a first and second region. In particular, the fusion proteins are identified following subjecting a sample comprising the proteins to a bead comprising an antibody to a first region, followed by subjecting the bead-antibody-fusion complex to a second antibody directed against the second region, thereby detecting the fusion protein. In particular aspects, the invention is employed to provide prognosis for an individual with cancer, to identify suitability for a particular cancer therapy, and/or to monitor response of a patient to a therapy, for example.

Abstract: The present invention concerns the detection of gene products resulting from chromosomal translocations, including fusion proteins comprising a first and second region. In particular, the fusion proteins are identified following subjecting a sample comprising the proteins to a bead comprising an antibody to a first region, followed by subjecting the bead-antibody-fusion complex to a second antibody directed against the second region, thereby detecting the fusion protein. In particular aspects, the invention is employed to provide prognosis for an individual with cancer, to identify suitability for a particular cancer therapy, and/or to monitor response of a patient to a therapy, for example.

Abstract: The present invention demonstrates that the diagnosis and prediction of clinical behavior in patients with hematologic malignancies, such as leukemia, can be accomplished by analysis of proteins present in a plasma sample. Thus, in particular embodiments the present invention uses plasma to create a diagnostic or prognostic protein profile of a hematologic malignancy comprising collecting plasma samples from a population of patients with hematologic malignancies; generating protein spectra from the plasma samples with or without fractionation; comparing the protein spectra with clinical data; and identifying protein markers in the plasma samples that correlate with the clinical data. Protein markers identified by this approach can then be used to create a protein profile that can be used to diagnose the hematologic malignancy or determine the prognosis of the hematologic malignancy. Potentially these specific proteins can be identified and targeted in the therapy of these malignancies.

Abstract: In accordance with the present invention there is provided a pharmaceutical combination useful for the treatment of cancer comprising at least one active compound of formula (I): and at least one further therapeutic agent chosen from a nucleoside analogue and/or a chemotherapeutic agents; and, a method of treating a patient having cancer comprising at least one active compound of formula (I), as defined above, and at least one further therapeutic agent chosen from a nucleoside analogue and/or a chemotherapeutic agents.

Abstract: In accordance with the present invention there is provided a pharmaceutical combination useful for the treatment of cancer comprising at least one active compound of formula (I): and at least one further therapeutic agent chosen from a nucleoside analogue and/or a chemotherapeutic agents; and, a method of treating a patient having cancer comprising at least one active compound of formula (I), as defined above, and at least one further therapeutic agent chosen from a nucleoside analogue and/or a chemotherapeutic agents.

Abstract: In a cellular mobile telecommunications system the position of a mobile station can be estimated in terms of its bearing and range from a cell site. A multi-element direction finding antenna at the cell site receives signals from the mobile station and a receiver circuit estimates the bearing using the relative phase of signals received at different antenna elements and estimates the range by measuring round trip delay of signals to and from the mobile station. Motion of the mobile station can introduce errors into the bearing estimate due to frequency offset and frequency spread when element sampling is non-simultaneous. Compensation for these errors is introduced by using signal samples successively received at the same antenna element to estimate Doppler frequency offset and spread. It is necessary to ensure accurate calibration of the direction finding antenna and the receiver circuit.

Abstract: The present invention provides a novel method for treating leukemia in a host that has been previously treated with a Bcr-Abl tyrosine kinase inhibitor comprising administering to the host a therapeutically effective amount of a compound having the formula I: wherein B is cytosine or 5-fluorocytosine and R is selected from H, monophosphate, diphosphate, triphosphate, carbonyl substituted with a C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, and and where in each Rc is independently selected from the group comprising H, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl an hydroxy protecting group.

Abstract: The present invention provides a novel method for treating leukemia in a host that has been previously treated with a Brc-Abl tyrosine kinase inhibitor comprising administering to the host a therapeutically effective amount of a compound having the formula I: 1

Abstract: In accordance with the present invention there is provided a pharmaceutical combination useful for the treatment of cancer comprising at least one active compound of formula (I): 1

Abstract: In a cellular mobile telecommunications system the position of a mobile station can be estimated in terms of its bearing and range from a cell site. A multi-element direction finding antenna at the cell site receives signals from the mobile station and a receiver circuit estimates the bearing using the relative phase of signals received at different antenna elements and estimates the range by measuring round trip delay of signals to and from the mobile station. Motion of the mobile station can introduce errors into the bearing estimate due to frequency offset and frequency spread when element sampling is non-simultaneous. Compensation for these errors is introduced by using signal samples successively received at the same antenna element to estimate Doppler frequency offset and spread. It is necessary to ensure accurate calibration of the direction finding antenna and the receiver circuit.

Abstract: A phase array antenna is monitored by applying to each element of the array in turn a signal known characteristics, detecting the signal output from the selected element as a result of the applied known signal, and comparing the detected signal with the applied signal whereby to monitor changes in the applied signal due to the signal path. The detection is preferably carried out using a single monitoring unit in the near-field of each antenna element. Alternatively the detection is carried out using a single source of applied signals a number of individual monitoring units one for each element of the array, and a switching device for selecting the element of the array to be monitored.

Abstract: A process for the production of acetic acid by carbonylation of methanol or a reactive derivative thereof by contacting the methanol or derivative with carbon monoxide in a liquid reaction composition comprising (a) acetic acid, (b) an iridium catalyst, (c) methyl iodide, (d) at least a finite quantity of water and (e) methyl acetate is improved by the use as promoter of at least one of ruthenium and osmium.

Abstract: Interference on a differential signal received at a first input to a digital data system processor is minimised or cancelled by summing a weighted portion of a local field signal with the differential signal. The local field signal may be a common-mode signal from the same line as the differential signal received at a second input. Weight may be a complex weight which shifts the local field signal in amplitude and phase. A weight control signal is derived from a comparison processor which compares the processed outputs of signal processors. Signal processors are preferably Discrete Multi-tone processors. Several iterations of this technique may be performed to establish an accurate weighting value.

Abstract: In a process for the liquid phase carbonylation of an alkyl alcohol such as methanol, and/or a reactive derivative thereof to produce the corresponding carboxylic acid and/or ester, in the presence of an iridium catalyst, an alkyl halide and water, the reaction is promoted by the presence of at least one promoter selected from cadmium, mercury, zinc, gallium, indium and tungsten, optionally with a co-promoter selected from ruthenium, osmium and rhenium.

Abstract: A process for the production of acetic acid by carbonylation of methanol or a reactive derivative thereof by contacting the methanol or derivative with carbon monoxide in a liquid reaction composition comprising (a) acetic acid, (b) an iridium catalyst, (c) methyl iodide, (d) at least a finite quantity of water and (e) methyl acetate is improved by the use as promoter of at least one of ruthenium and osmium.